Form 4: Kiniksa Pharmaceuticals Executive Exercises and Sells Shares Under 10b5-1 Plan

A Kiniksa Pharmaceuticals executive, Michael R. Megna, executed share option exercises and sales under a pre-arranged 10b5-1 trading plan.

Summary

• Michael R. Megna, Chief Accounting Officer of Kiniksa Pharmaceuticals, engaged in transactions involving Class A Ordinary Shares.
• On November 27, 2024, Megna exercised options to acquire 8,637 shares at $11.10 per share and then sold the same amount of shares at a weighted average price of $22.45.
• On November 29, 2024, Megna exercised options to acquire 9 shares at $11.10 per share and then sold the same amount of shares at a weighted average price of $22.45.
• These transactions were executed under a 10b5-1 trading plan established on July 24, 2024.
• Following these transactions, Megna's direct holdings of Class A Ordinary Shares decreased from 35,165 to 26,528.
• Megna also holds options for 22,814 Class A Ordinary Shares after the transactions.

Sentiment

Score: 5

Explanation: The document reflects routine executive share transactions under a pre-arranged plan, which is neither positive nor negative for the company's overall outlook.

Industry Context

Executive share transactions are a common occurrence in publicly traded companies, often conducted under pre-arranged trading plans to avoid accusations of insider trading. The use of a 10b5-1 plan indicates that these transactions were planned in advance and not based on any non-public information.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a standard practice among executives at publicly traded companies, including those in the pharmaceutical sector such as Regeneron Pharmaceuticals and Vertex Pharmaceuticals.
• The reported transactions are typical for executives exercising stock options and selling shares for personal financial management.
• The price range of $22.45 to $22.465 for the share sales is consistent with market trading prices at the time of the transactions.

Stakeholder Impact

• The transactions may have a minor impact on the share price due to the volume of shares traded, but this is likely to be minimal given the pre-planned nature of the trades.
• The transactions do not have a direct impact on employees, customers, or suppliers.

Key Dates

Keywords

Kiniksa Pharmaceuticals, Share Transactions, Form 4, 10b5-1 Plan, Executive Trading, Michael R. Megna, Share Options